The Extracellular RNA Communication Consortium has published 500+ research articles since its inception in 2013. Articles in the category “Therapeutics” are listed here in reverse chronological order. Each article is tagged by category; you can browse different categories using the drop-down menu at the top of the page or by clicking on the tags of multi-category articles.
Petrescu GED et al.
MicroRNA based theranostics for brain cancer: Basic principles.
J Exp Clin Cancer Res (2019) 38:231.
Tapparo M et al.
Ghai V et al.
Watts JK, Brown RH & Khvorova A.
Nucleic acid therapeutics for neurological diseases.
Neurotherapeutics (2019) 16:245-247.
Bach DH, Lee SK & Sood AK.
Mol Ther Nucleic Acids (2019) 16:118-129.
Krichevsky AM & Uhlmann EJ.
Neurotherapeutics (2019) 16:319-347.
Gulei D et al & .
CRISPR-based RNA editing: Diagnostic applications and therapeutic options.
Expert Rev Mol Diagn (2019) 19:83-88.
Kanlikilicer P et al.
EBioMedicine (2018) 38:100-112.
Teng Y et al.
Plant-derived exosomal microRNAs shape the gut microbiota.
Cell Host Microbe (2018) 24:637-652.e8.
Wang QL et al.
Theranostics (2018) 8:4912-4924.
Moirangthem A & Patel T.
Haraszti RA et al.
Optimized cholesterol-siRNA chemistry improves productive loading onto extracellular vesicles.
George J, Yan IK & Patel T.
Biscans A et al.
Wang JH et al.
Mol Cancer Ther (2018) 17 :1133-1142.
Matsuda A & Patel T.
Milk-derived extracellular vesicles for therapeutic delivery of small interfering RNAs.
Methods Mol Biol (2018) 1740:187-197.
Lankford KL et al.
Chen X et al.
RNA interference-based therapy and its delivery systems.
Cancer Metastasis Rev (2018) 37:107-124.
Pi F et al.
Nat Nanotechnol (2018) 13:82-89.
Haraszti RA et al.
Wu X et al & .
The many faces of long noncoding RNAs in cancer.
Antioxid Redox Signal (2018) 29:922-935.
Bei Y et al.
Basic Res Cardiol (2017) 112:38.
Bruno S et al.
Tissue Eng Part A (2017) 23:1262-1273.
Ochocinska MJ et al.
Fluids Barriers CNS (2017) 14:12.
Haga H et al.
Liver Transpl (2017) 23:791-803.
Sutaria DS et al.
Pharm Res (2017) 34:1053-1066.
Deng Z et al.
Haga H et al.
Stem Cells Transl Med (2017) 6:1262-1272.
Maas SL, Breakefield XO & Weaver AM.
Extracellular vesicles: Unique intercellular delivery vehicles.
Trends Cell Biol (2017) 27:172-188.
Srivastava A et al.
Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells.
Matsuda A et al.
MicroRNAs as paracrine signaling mediators in cancers and metabolic diseases.
Best Pract Res Clin Endocrinol Metab (2016) 30:577-590.
Katsiougiannis S et al.
Shah MY et al.
microRNA therapeutics in cancer – an emerging concept.
Didiot MC et al.
Exosome-mediated delivery of hydrophobically modified siRNA for Huntingtin mRNA silencing.
Maji S et al.
In vitro toxicology studies of extracellular vesicles.
J Appl Toxicol (2017) 37:310-318.
Paladini L et al.
Targeting microRNAs as key modulators of tumor immune response.
J Exp Clin Cancer Res (2016) 35:103.
Srivastava A et al.
Exploitation of exosomes as nanocarriers for gene-, chemo-, and immune-therapy of cancer.
J Biomed Nanotechnol (2016) 12:1159-73.
Wang JQ et al.
Extracellular vesicle-mediated reversal of paclitaxel resistance in prostate cancer.
Crit Rev Oncog (2015) 20:407-17.
Chaluvally-Raghavan P et al.
Wen S et al.
Wu SY et al.
A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.
Teng Y et al.
Hall J et al.
Cell Mol Neurobiol (2016) 36:417-27.
Parasramka MA et al.
Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma.
Pharmacol Ther (2016) 161:67-78.
Related Pathway
Lener T et al.
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper.
J Extracell Vesicles (2015) 4:30087.
Rupaimoole R et al.
Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.
Oncogene (2016) 35:4312-20. Related blog post
Rupaimoole R et al.
Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis.
Shields BB et al.
A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
Mol Syst Biol (2015) 11:842.
Related Pathways: 1, 2
Sercombe L et al.
Advances and challenges of liposome assisted drug delivery.
Zhuang X et al.
Ginger-derived nanoparticles protect against alcohol-induced liver damage.
J Extracell Vesicles (2015) 4:28713.
Zhuang X et al.
Chira S et al.
Progresses towards safe and efficient gene therapy vectors.
Oncotarget (2015) 6:30675-703.
Quesenberry PJ et al.
J Extracell Vesicles (2015) 4:27575.
Ainsztein AM et al.
The NIH Extracellular RNA Communication Consortium.
J Extracell Vesicles (2015) 4:27493.
Camussi G & Quesenberry PJ.
Perspectives on the potential therapeutic uses of vesicles.
Exosomes Microvesicles (2013) 1:6.
Collino F et al.
AKI recovery induced by mesenchymal stromal cell-derived extracellular vesicles carrying microRNAs.
J Am Soc Nephrol (2015) 26:2349-60.
Wang Q et al.
Simonson B & Das S.
MicroRNA therapeutics: the next magic bullet?
Mini Rev Med Chem (2015) 15:467-74.
Xiao J et al.
A snapshot of genetic and epigenetic basis of arrhythmia and heart failure.
Ciccone M, Calin GA & Perrotti D.
From the biology of PP2A to the PADs for therapy of hematologic malignancies.
Nick AM et al.
A framework for a personalized surgical approach to ovarian cancer.
Nat Rev Clin Oncol (2015) 12:239-45.
Ozcan G et al.
Preclinical and clinical development of siRNA-based therapeutics.
Adv Drug Deliv Rev (2015) 87:108-19.
George J & Patel T.
Noncoding RNA as therapeutic targets for hepatocellular carcinoma.
Semin Liver Dis (2015) 35:63-74.
Gonzalez-Villasana V et al.
Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer.
Clin Cancer Res (2015) 21:2127-37.
Related Pathway
Choi HJ et al.
Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches.
Cancer Metastasis Rev (2015) 34:19-40.
Srivastava A et al.
Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment.
Curr Gene Ther (2015) 15:182-92.
Rupaimoole R et al.
Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.
Sato-Kuwabara Y et al.
Kawikova I & Askenase PW.
Diagnostic and therapeutic potentials of exosomes in CNS diseases.
Gyorgy B et al.
Therapeutic applications of extracellular vesicles: Clinical promise and open questions.
Annu Rev Pharmacol Toxicol (2015) 55:439-64.
Krzeszinski JY et al.
MiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.
Nature (2014) 512:431-5.
Related Pathway
Vader P, Breakefield XO & Wood MJ.
Extracellular vesicles: Emerging targets for cancer therapy.
Trends Mol Med (2014) 20:385-393.
Grange C et al.
Int J Mol Med (2014) 33:1055-63.
Pusic AD, Pusic KM & Kraig RP.
What are exosomes and how can they be used in Multiple Sclerosis therapy?
Expert Rev Neurother (2014) 14:353-5.
Zhaorigetu S et al.
J Liposome Res (2014) 24:182-90.
Ozpolat B, Sood AK & Lopez-Berestein G.
Liposomal siRNA nanocarriers for cancer therapy.
Adv Drug Deliv Rev (2014) 66:110-6.
Related Pathway
Pusic AD et al.
IFNgamma-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
J Neuroimmunol (2014) 266:12-23.
Wang Q et al.
Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids.
Gonda DD et al.
